Novo Nordisk strikes second licensing deal since frosty capital-markets day

•27d ago

Novo Nordisk strikes second licensing deal since frosty capital-markets day

Tap title to read story

0:00 / 0:40

Novo Nordisk secured a licensing agreement valued at up to $2.6 billion with Jiangsu Hengrui Pharmaceuticals for oral dual agonist HRS-1596, targeting obesity and type 2 diabetes. This marks the second major partnership in under a week, following a drug-delivery technology deal with Sweden's Nanexa exceeding $1 billion. The rapid-fire acquisitions address investor concerns regarding upcoming patent expirations around 2030 and 2032, highlighting aggressive portfolio expansion in the cardiometabolic sector. Wall Street analysts questioned long-term growth vectors during a recent Capital Markets Day, prompting management to bolster its late-stage pipeline externally. The agreement includes a $300 million upfront payment alongside development and commercialization milestones, granting Novo exclusive global rights outside select Asian markets. Phase I clinical trials for the candidate are already cleared in China. Both transactions reflect a strategic urgency to diversify assets, counter looming biosimilar competition, and secure next-generation delivery innovations to sustain market dominance in metabolic therapeutics globally.

Published 2026-09-29 10:25:38 UTC · Published by JQJO

Prepared by Noormahi M. · AI assisted

More context

Timeline

On 2026-09-18, Novo Nordisk hosted its annual investor Capital Markets Day presentation.
On 2026-09-22, Novo Nordisk announced a drug delivery partnership with Nanexa.
On 2026-09-26, Novo Nordisk finalized a licensing deal with Jiangsu Hengrui.
On 2026-09-27, financial analysts published critical reviews regarding upcoming patent expirations.
On 2026-09-28, market observers noted increased acquisition activity across pharmaceutical sectors.
On 2026-09-29, industry reports evaluated the clinical potential of oral HRS-1596.
In coming months, regulatory filings for clinical trial transitions will proceed.
Throughout 2027, preclinical and early clinical evaluations are expected to advance.
By 2030, initial major blockbuster patent expirations begin taking effect globally.
By 2032, secondary patent cliffs challenge existing company revenue streams significantly.

Why it matters

Immediate US impact: Immediate US impact remains minimal pending further clinical trial advancements. Possible long-term US impact: Long-term US impact shapes future metabolic drug pricing and options. Most affected groups: Most affected groups include diabetes patients, investors, and competing pharmaceutical firms. Reader priority: Readers should prioritize official investor relations and regulatory filing updates.

Coverage notes

Left: Framing emphasizes corporate capital allocation and impacts on health access. Center: Framing focuses neutrally on financial transactions and patent cliff strategies. Right: Framing highlights market competition, investor value, and commercial innovation growth.